Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) and/or (G13D mutant) inhibitors reported to be useful for the treatment of cancer.

Neurobiogen Co Ltd. has synthesized monoamine oxidase-B (MAO-B) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Bristol Myers Squibb Co. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases.

Gilead Sciences Inc. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Cellarity Inc. has divulged DCN1-like protein 1 (DCUN1D1; RP42) and/or DCN2 inhibitors reported to be useful for treatment of sickle cell and thalassemia disorder.

Korea Institute of Science and Technology has identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Yingli Pharmaceutical Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Bristol Myers Squibb Co. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Pillai Universal LLC has prepared and tested compounds acting as protein kinase inhibitors reported to be useful for the treatment of cancer.

Halda Therapeutics LLC has synthesized heterobifunctional compounds able to bind both androgen receptor and bromodomain-containing protein 4 (BRD4; HUNK1) reported to be useful for the treatment of cancer.